GO
| HSI1 | 24,657.06 | -304.89 | 363.97B |
| HSCEI1 | 8,341.36 | -95.27 | 98.64B |
| Back Zoom + Zoom - Block Traded | |
|
2026-06-05 10:58:02 On June 4 (yesterday), Citi invited a senior pharmaceutical innovation policy expert to host an expert conference call. According to the expert, authorities recognize that the core competitive advantage of the industry lies in efficient clinical validation rather than in the invention of technology itself. Therefore, regulators will continue to encourage compliant out-licensing of innovative drugs. Stricter regulatory measures would only target extreme cases involving the export of critical core technologies. The expert also noted that companies with offshore IP structures, offshore clinical trial data, and a single-asset out-licensing model will be best positioned. Citi’s top picks in the pharmaceuticals/biotechnology sector are HENGRUI PHARMA (01276.HK), CSPC PHARMA (01093.HK), ASCLETIS-B (01672.HK) and INNOVENT BIO (01801.HK). The broker believed the market has overreacted to potential policies restricting biopharmaceutical technology exports, creating good buying opportunities for investors. ~ AASTOCKS Financial News Website: www.aastocks.com | |